genuine question about oral GLP-1 that I am slightly embarrassed to ask
genuine question about oral GLP-1 that I am slightly embarrassed to ask. I am not trying to be the "source?" guy. I would just like a source. Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve. Milligram comparisons…
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.
the tolerability profile reads broadly similar to the class
Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.
This. The absence of food and water timing restrictions is the practical difference people will actually notice.
small molecule, not a peptide, and that changes everything about it
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
phase 3 is where the comparison becomes fair